Human leukocyte antigen DR isotype (HLA-DR)

Human leukocyte antigen DR isotype (HLA-DR) is a polymorphic Major Histocompatibility Complex (MHC) class II receptor primarily expressed on professional antigen-presenting cells, such as dendritic cells, B cells, and macrophages. The peptide-binding groove is the functional core of the HLA-DR molecule, consisting of an open-ended cleft formed by the alpha-1 and beta-1 domains that accommodates antigenic peptides typically 12 to 20 amino acids in length. This groove plays a pivotal role in the adaptive immune system by presenting exogenous peptides to CD4+ T-helper cells, a process essential for initiating immune responses against pathogens and maintaining self-tolerance. Dysregulation or specific allelic variations of the groove, such as the shared epitope in HLA-DRB1, are strongly associated with autoimmune diseases like rheumatoid arthritis and multiple sclerosis, where the groove preferentially binds self-antigens. Therapeutic targeting of the HLA-DR peptide-binding groove involves competitive inhibitors like glatiramer acetate, which displace pathogenic peptides, or small molecules that can inadvertently alter the presented peptide repertoire, leading to hypersensitivity reactions. Understanding the structural pockets (P1, P4, P6, P7, P9) within the groove is critical for developing vaccines and immunotherapies aimed at modulating T-cell activation.

Other names

MHC class II DRHLA-DR antigenHLA-DRB1HLA-DRAMajor histocompatibility complex, class II, DR

Drugs targeting the HLA-DR peptide-binding groove primarily act through competitive inhibition, where they displace antigenic peptides to prevent T-cell activation, or through the altered peptide repertoire model, where the drug binds to the groove and changes the specificity of self-peptide presentation, potentially triggering hypersensitivity reactions.